Recent progress in the pathogenesis of nephrotic proteinuria

Critical Reviews in Clinical Laboratory Sciences

Volumn 45, Issue 2, 2008, Pages 139-220

  Tesař, Vladimír ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetic nephropathy; Focal segmental glomerulosclerosis; Hereditary proteinuria syndrome; Membranous nephropathy; Minimal change disease; Nephrin; Nephrotic syndrome; Podocin; Podocyte; Proteinuria; Slit diaphragm

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ACTININ; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CD24 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROGLYCAN; EVEROLIMUS; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTEGRIN RECEPTOR; MEVALONIC ACID; NCK PROTEIN; NEPHRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PODOCIN; RAPAMYCIN; RETINOIC ACID; ROSCOVITINE; SIMVASTATIN; TRANSCRIPTION FACTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; WORTMANNIN;

CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL JUNCTION; CELL STRUCTURE; CHEMICAL STRUCTURE; CONGENITAL NEPHROTIC SYNDROME; DENYS DRASH SYNDROME; DIABETIC NEPHROPATHY; DIAPHRAGM; DISEASE COURSE; ENDOCYTOSIS; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; FOCAL GLOMERULOSCLEROSIS; FRASIER SYNDROME; GENETIC DISORDER; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROMOLECULE; MUTATION; NAIL PATELLA SYNDROME; NEPHROTIC SYNDROME; NERVE CELL; NONHUMAN; OBESITY; PATHOGENESIS; PERMEABILITY; PIERSON SYNDROME; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

EID: 42149127082     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360801934865     Document Type: Review

References (406)

1. Kestila M, Lenkkeri U, Mannikko M, Lameerin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan CE, Peltonen L, Holmberg C, Olsen A, Tryggvason K. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1: 575-582.
2. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998; 338: 1202-1211.
3. Tesar V, Zima T, Kalousova M. Pathobiochemistry of nephrotic syndrome. Adv Clin Biochem 2002; 37: 173-218.
4. Smithies O. Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci USA 2003; 100: 4108-4113.
5. Deen WM. What determines glomerular capillary permeability? J Clin Invest 2004; 114: 1412-1414.
6. Guasch A, Myers BD. Determinants of glomerular hypofiltration in nephrotic patients with minimal change nephropathy. J Am Soc Nephrol 1994; 4: 1571-1581.
7. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63: 809-825.
8. Van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. A monoclonal antibody against GBM heparan sulfate induces an acute selectve proteinuria in rats. Kidney Int 1992; 41: 115-123.
9. Kawachi H, Kurihara H, Topham PS, Brown D, Shia MA, Orikasa M, Shimizu F, Salant DJ. Slit diaphragm-reactive nephritogenic MAb 5-1-6 alters expression of ZO-1 in rat podocytes. Am J Physiol 1997; 273: F984-F993.
10. Caulfield JP, Farquhar MP. The permeability of glomerular capillaries to graded dextrans: identification of the basement membrane as the primary filtration barrier. J Cell Biol 1974; 63: 883-903.
11. Kanwar YS, Liu ZZ, Kashihara N, Wallner EI: Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 1991; 11: 390-413.
12. Rossi M, Morita H, Sormunen R, Airenne S, Kreivi M, Wang L, Fukai N, Olsen BR, Tryggvason K, Soininen R. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 2003; 22: 236-245.
13. Jarad G, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes podocyte abnormalities in Lamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 2006; 116: 2272-2279.
14. Farquhar MG. The glomerular basement membrane: not gone, just forgotten. J Clin Invest 2006; 116: 2090-2093.
15. Yoshioka N, Ito H, Akamatsu R, Hazikano H, Okada S, Matsuo T. Glomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch Pathol Lab Med 1986; 110: 394-398.
16. Eyre J, Ioannou K, Grubb BD, Saleem MA, Mathieson PW, Brunskill NJ, Christensen EI, Topham PS. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am J Physiol Renal Physiol 2007; 292: F674-F681.
17. Bulger RE, Eknoyan G, Purcell DJ, Dobyan DC. Endothelial characteristic of glomerular capillaries in normal, mercuric-chloride-induced, and gentamicin-induced acute renal failure in the rat. J Clin Invest 1983; 72: 128-141.
18. Sawada H, Stukenbrok H, Kerjaschki D, Farquhar MG. Epithelial polyanion (podocalyxin) is found on the sides but not the soles of the foot processes of the glomerular epithelium. Am J Pathol 1986; 125: 309-318.
19. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13: 9-15.
20. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
21. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
22. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 2006; 17: 2383-2389.
23. Hudson BG, Reeder ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993; 268: 26033-26036.
24. Tryggvason K, Wartiovara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001; 10: 543-549.
25. Badens C, Praga M, Tazón B, Heidet L, Arrondel C, Armengol A, Andrés A, Morales E, Camacho A, Lens X, Dávila S, Mila M, Antignac C, Darnell A, Torra R. Mutations in the COL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 2002; 13: 1248-1254.
26. Noakes PG, Miner JH, Gautam M, Cunningham JM, Sanes JR, Merlie JP. The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1. Nat Genet 1995; 10: 400-406.
27. Dandapani SV, Pollak MR. The glomerular filter: biologic and genetic complexity. Kidney Int 2006; 70: 980-982.
28. Zenker M, Aigner T, Wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wuhl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dotsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis A. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004; 13: 2625-2632.
29. Hasselbacher K, Wiggins RC, Matejas V, Hinkes BG, Mucha B, Hoskins BE, Ozaltin F, Nurnberg G, Becker C, Hangan D, Pohl M, Kuwertz-Broking E, Griebel M, Schumacher V, Royer-Pokora B, Bakkaloglu A, Nurnberg P, Zenker M, Hildebrandt F. Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int 2006; 70: 1008-1012.
30. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci USA 1979; 76: 1303-1307.
31. Hassel JR, Robey PG, Barrach HJ, Wilczek J, Rennard SI, Martin GR. Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc Natl Acad Sci USA 1980; 77: 4494-4498.
32. Groffen AJ, Ruegg MA, Dijkman H, van de Velden TJ, Buskens CA, van den Born J, Assmann KJ, Monnens LA, Veerkamp JH, van den Heuvel LP. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998; 46: 19-27.
33. Rops AL, van der Vlag J, Lensen JE, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, Berden JH. Heparan sulfate proteglycans in glomerular inflammation. Kidney Int 2004; 65: 768-785.
34. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane in aminonucleoside nephrosis. J Cell Biol 1980; 86: 688-693.
35. Caulfield JP, Farquhar MG. Loss of anionic sites from the glomerular basement membrane in aminonucleoside nephrosis. Lab Invest 1978; 39: 505-512.
36. Harvey SJ, Miner J. Podocyte-derive agrin is responsible for glomerular basement membrane anionic charge. J Am Soc Nephrol 2005; 16:1A, abstract.
37. Morita H, Yoshimura A, Inui K, Ideura T, Watanabe H, Wang L, Soininen R, Tryggvason K. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 2005; 16: 1703-1710.
38. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002; 39: 899-919.
39. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
40. Marshall CB, Shankland SJ. Cell cycle and glomerular disease: a minireview. Nephron Exp Nephrol 2006; 102: e39-e48.
41. Kriz W, Hackenthal E, Nobiling R, Sakai T, Elger M, Hahnel B. A role for podocytes to counteract capillary wall distention. Kidney Int 1994; 45: 369-376.
42. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
43. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61.
44. Schmieder S, Nagai M, Orlando RA, Takeda T, Farquhar MG. Podocalyxin activates RhoA and induces actin reorganization through NHERF1 and ezrin in MCDK cells. J Am Soc Nephrol 2004; 15: 2289-2298.
45. Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, Furthmayr H, Farquhar MG. The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 2001; 12: 1589-1598.
46. Takeda T, McQuistan T, Orlando RA, Farquhar MG. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 2001; 108: 289-301.
47. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D. Podoplanin, a novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151: 1141-1152.
48. Farquhar M, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: Megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6: 35-47.
49. Kriz W, Elger M, Mundel P, Lemley KV. Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 1995; 5: 1731-1739.
50. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001; 12: 413-422.
51. Endlich N, Endlich K. Stretch, tension and adhesion - adaptive mechanisms of the actin cytoskeleton in podocytes. Eur J Cell Biol 2006; 85: 229-234.
52. +channel: potential implications for the control of glomerular filtration. J Am Soc Nephrol 2004; 15: 2981-2987.
53. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37: 739-744.
54. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Resonberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804.
55. Huber TB, Gloy J, Henger A, Schollmeyer P, Greger R, Mundel P, Pavenstadt H. Catecholamines modulate podocyte function. J Am Soc Nephrol 1998; 9: 335-345.
56. Sharma R, Lovell HB, Wiegmann TB, Savin VJ. Vasoactive substances induce cytoskeletal changes in cultured rat glomerular epithelial cells. J Am Soc Nephrol 1992; 3: 1131-1138.
57. Pavenstädt H. The charge for going by foot: modifying the surface of podocytes. Exp Nephrol 1998; 6: 98-103.
58. Rodriguez OC, Schaefer AW, Mandato CA, Forscher P, Bement WM, Waterman-Storer CM. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nature Cell Biol 2003; 5: 599-609.
59. Gao SY, Li CY, Chen J, Pan L, Saito S, Terashita T, Saito K, Miyawaki K, Shigemoto K, Mominoki K, Matsuda S, Kobayashi N. Rho-ROCK signal pathway regulates microtubule-based process formation of cultured podocytes - inhibition of ROCK promoted process elongation. Nephron Exp Nephrol 2004; 97: e49-e61.
60. Cybulsky AV, Carbonetto S, Huang Q, McTavish AJ, Cyr MD. Adhesion of rat glomerular epithelial cells to extracellular matrices. Role of β1 integrins. Kidney Int 1992; 42: 1099-1106.
61. Kojima K, Davidovits A, Poczewski H, Langer B, Uchida S, Nagy-Bojarski K, Hovorka A, Sedivy R, Kerjaschki D. Podocyte flattening and disorder of glomerular basement membrane are associated with splitting of dystroglycan-matrix interaction. J Am Soc Nephrol 2004; 15: 2079-2089.
62. Teixeira V, Blattner SM, Li M, Anders HJ, Cohen CD, Edenhofer I, Calvaresi N, Merkle M, Rastaldi MP, Kretzler M. Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 2005; 67: 514-523.
63. Critchley DR. Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. Biochem Soc Trans 2004; 32: 831-836.
64. Kreidberg JA. Podocyte differentiation and glomerulogenesis. J Am Soc Nephrol 2003; 14: 806-814.
65. Usui J, Kurihara H, Shu Y, Tomari S, Kanemoto K, Koyama A, Sakai T, Takahashi T, Nagata M. Localization of intercellular adherens junction protein p120 catenin during podocyte differentiation. Anat Embryol 2003; 206: 175-184.
66. Takeda T, Go WY, Orlando RA, Farquhar MG. Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell 2000; 11: 3219-3232.
67. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354: 1387-1401.
68. Moeller MJ. Dynamics at the slit diaphragm - is nephrin actin? Nephrol Dial Transplant 2007; 22: 37-39.
69. Andrews PM. Investigations of cytoplasmic contractile and cytoskeletal elements in the kidney glomerulus. Kidney Int 1981; 20: 549-562.
70. Shirato I, Sakai T, Kimura K, Tomino Z, Kriz W. Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis. Am J Pathol 1996; 148: 1283-1296.
71. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, Honey K, Ishidoh K, Kominami E, Kreidberg JA, Tomino Y, Mundel P. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and α3 integrin. J Biol Chem 2004; 279: 34827-34832.
72. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108: 1583-1587.
73. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int 2005; 67: 2101-2113.
74. Van den Berg JG, Weerman MA, Assmann KJ, Weening JJ, Florquin S. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66: 1901-1906.
75. Garovic VC, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, Kalluri R, Grande JP. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007; 22: 1136-1143.
76. Yu Y, Leng CG, Kato Y, Ohno S. Ultrastructural study of glomerular capillary loops at different perfusion pressures as revealed by quick-freezing, freeze-substitution and conventional fixation methods. Nephron 1997; 76: 452-459.
77. Rodewald R, Karnovsky MJ. Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 1974; 60: 621-624.
78. Kurihara H, Anderson JM, Farquhar MG. Diversity among tight junctions in rat kidney: Glomerular slit diaphragms and endothelial junctions express only one isoform of the tight junction protein ZO-1. Proc Natl Acad Sci USA 1992; 89: 7075-7079.
79. Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol 2000; 11: 1-8.
80. Yaoita E, Yao J, Yoshida Y, Morioka T, Nameta M, Takata T, Kamiie J, Fujinaka H, Oite T, Yamamoto T. Up-regulation of connexin43 in glomerular podocytes in response to injury. Am J Pathol 2002; 161: 1597-1606.
81. Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev 2003; 83: 1359-1400.
82. Silverstein DM, Urban M, Gao Y, Mattoo TK, Spray DC, Rozental R. Renal morphology in connexin43 knockout mice. Pediatr Nephrol 2001; 16: 467-471.
83. Sawai K, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Yoshioka T, Takeda R, Sugawara A, Kuwahara T, Saleem MA, Ogawa O, Nakao K. Redistribution of connexin43 expression in glomerular podocytes predicts poor renal prognosis in patients with type 2 diabetes and overt nephropathy. Nephrol Dial Transplant 2006; 21: 2472-2477.
84. Orikasa M, Matsui K, Oite T, Shimizu F. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol 1988; 141: 807-814.
85. Kawachi H, Abrahamson DR, John PL, Goldstein DJ, Shia MA, Matsui K, Shimizu F, Salant DJ. Developmental expression of the nephritogenic antigen of monoclonal antibody 5-1-6. Am J Pathol 1995; 147: 823-833.
86. Topham PS, Kawachi H, Haydar SA, Chugh S, Addona TA, Charron KB, Holzman LB, Shia M, Shimizu F, Salant DJ. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest 1999; 104: 1559-1566.
87. Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999; 10: 2440-2445.
88. Tryggvason K, Ruotsalainen V, Wartiovaara J. Discovery of the congenital nephrotic syndrome gene discloses the structure of the mysterious molecular sieve of the kidney. Int J Dev Biol 1999; 43: 445-451.
89. Putaala H, Soininen R, Klipelainen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001; 10: 1-8.
90. Wang SX, Ahola H, Palmen T, Solin ML, Luimula P, Holthofer H. Recurrence of nephrotic syndrome after transplantation in CNF is due to autoantibodies to nephrin. Exp Nephrol 2001; 9: 327- 331.
91. Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Makela E, Sandin S, Ruotsalainen V, Cheng RH, Jalanko H, Skoglund U, Tryggvason K. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 2004; 114: 1475-1483.
92. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, Reponen P, Tryggvason K, Camussi G. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158: 1723-1731.
93. Patari A, Forsblom C, Havana M, Taipale H, Groop PH, Holthofer H. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003; 52: 2969-2974.
94. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 2001; 114: 131-139.
95. Takano Y, Yamauchi K, Hiramatsu N, Kasai A, Hayakawa K, Yokouchi M, Yao J, Kitamura M. Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol 2007; 292: F1573-F1582.
96. Takano Y, Yamauchi K, Hayakawa K, Hiramatsu N, Kasai A, Okamura M, Yokouchi M, Shitamura A, Yao J, Kitamura M. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett 2007; 581: 421-426.
97. Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR. Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to nephrin. Mol Cell Biol 2001; 21: 4829-4836.
98. Gerke P, Sellin L, Kretz O. NEPH2 is located at the glomerular slit diaphragm, interacts with nephrin and is cleaved from podocytes by metalloproteinases. J Am Soc Nephrol 2005; 16: 1693-1702.
99. Michaud JL, Kennedy CR. The podocyte in health and disease: insights from the mouse. Clin Sci 2007; 112: 325-335.
100. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MD, Niaudet P, Antignac C. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-354.
101. Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W, Shaw AS, Holzman LB, Mundel P. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629.
102. Harder T. Lipid raft domains and protein networks in T-cell receptor signal transduction. Curr Opin Immunol 2004; 16: 353-359.
103. Luimula P, Sandstrom N, Novikov D, Holthofer H. Podocytes-associated molecules in puromycin aminonucleoside nephrosis of the rat. Lab Invest 2002; 82: 713-718.
104. Miner JH, Morello R, Andrews KL, Li C, Antignac C, Shaw AS, Lee B. Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. J Clin Invest 2002; 109: 1065-1072.
105. Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, Widder P, Rosenberger F, van der Merwe PA, Allen PM, Shaw AS. A novel adaptor protein orchestrates receptor patterning and cytoskeleletal polarity in T-cell contacts. Cell 1998; 94: 667-677.
106. Shih NY, Li J, Karpitskij V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999; 286: 312-315.
107. Tossidou I, Kardinal C, Peters I, Kriz W, Shaw A, Dikic I, Tkachuk S, Dumler I, Haller H, Schiffer M. CD2AP/CIN85 balance determines RTK-signaling response in podocytes. J Biol Chem 2007; 282: 7457-7464.
108. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol 2004; 15: 1382-1391.
109. Patrakka J, Xiao Z, Nukui M, Takemoto M, HeL, Oddsson A, Perisic L, Kaukinen A, Al-Khalili A, Szigyarto C, Uhlén M, Jalanko H, Betsholtz C, Tryggvason K. Expression and subcellular distribution of novel glomerulus-associated proteins dendrin, Ehd3, Sh2d4a, Plekhh2, and 2310066E14Rik. J Am Soc Nephrol 2007; 18: 689-697.
110. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397.
111. Lahdenpera J, Kilpelainen P, Liu XL, Pikkarainen T, Reponen P, Ruotsalainen V, Tryggvason K. Clustering-induced tyrosine phosphorylation of nephrin by src family kinases. Kidney Int 2003; 64: 404-413.
112. Verma R, Wharram B, Kovari I, Kunkel R, Nihalani D, Wary KK, Wiggins RC, Killen P, Holzman LB. Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin. J Biol Chem 2003; 278: 20716-20723.
113. Wang SX, Mene P, Holthofer H. Nephrin mRNA regulation by protein kinase C. J Nephrol 2001; 14: 98-103.
114. Liu XL, Kilpeläinen P, Hellman U, Sun Y, Wartiovaara J, Morgunova E, Pikkarainen T, Yan K, Jonsson AP, Tryggvason K. Characterization of the interactions of the nephrin intracellular domain. Evidence that the scaffolding protein IQGAP1 associates with nephrin. FEBS J 2005; 272: 228-243.
115. Meier M, Menne J, Park JK, Holtz M, Gueler F, Kirsch T, Schiffer M, Mengel M, Lindschau C, Leitges M, Haller H. Deletion of protein kinase C-ε signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol 2007; 18: 1190-1198.
116. Verma R, Kovari I, Soofi A, Nihalani D, Patrie K, Holzman LB. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 2006; 116: 1346-1359.
117. Yu CC, Yen TS, Lowell CA, DeFranco AL. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr Biol 2001; 11: 34-38.
118. Huber TB, Simons M, Hartleben B, Sernetz L, Schmidts M, Gundlach E, Saleem MA, Walz G, Benzing T. Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet 2003; 12: 3397-3405.
119. Li H, Lemay S, Aoudjit L, Kawachi H, Takano T. Src-family kinase Fyn phosphorylates the cytoplasmic domain of nephrin and modulates its interaction with podocin. J Am Soc Nephrol 2004; 15: 3006-3015.
120. Quack I, Rump LC, Gerke P, Walther I, Vinke T, Vonend O, Grunwald T, Sellin L. β-arrestin2 mediates nephrin endocytosis and impairs slit diaphragm integrity. Proc Natl Acad Sci USA 2006; 103: 14110-14115.
121. Huber TB, Hartleben B, Kim J, Schmidts M, Schermer B, Keil A, Egger L, Lecha RL, Borner C, Pavenstadt H, Shaw AS, Walz G, Benzing T. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 2003; 23: 4917-4928.
122. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288: F48-F57.
123. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-968.
124. Tryggvason K, Pikkarainen T, Patrakka J. Nck links nephrin to actin in kidney podocytes. Cell 2006; 125: 221-224.
125. Buday L, Wunderlich L, Tamás P. The Nck family of adapter proteins: regulators of actin cytoskeleton. Cell Signal 2002; 14: 723-731.
126. Jones N, Blasutig IM, Eremina V, Ruston JM, Bladt F, Li H, Huang H, Larose L, Li SS, Takano T, Quaggin SE, Pawson T. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006; 440: 818-823.
127. Huber TB, Schmidts M, Gerke P, Schermer B, Zahn A, Hartleben B, Sellin L, Walz G, Benzing T. The carboxyl terminus of Neph family members binds to the PDZ domain protein zonula occludens-1. J Biol Chem 2003; 278: 13417-13421.
128. Lehtonen S, Lehtonen E, Kudlicka K, Holthofer H, Farquhar MG. Nephrin forms a complex with adherens junction proteins and CASK in podocytes and in Madin-Darby canine kidney cells expressing nephrin. Am J Pathol 2004; 165: 923-936.
129. Lehtonen S, Ryan JJ, Kudlicka K, Iino N, Zhou H, Farquhar MG. Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrin, and alpha-actinin are components of the nephrin multiprotein complex. Proc Natl Acad Sci USA 2005; 102: 9814-9819.
130. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629-635.
131. Noritake J, Watanabe T, Sato K, Wang S, Kaibuchi K. IQGAP1: a key regulator of adhesion and migration. J Cell Sci 2005; 118: 2085-2092.
132. Ho YD, Joyal JL, Li Z, Sacks DB. IQGAP1 integrates Ca2+/calmodulin and Cdc42 signaling. J Biol Chem 1999; 274: 464-470.
133. Li S, Wang Q, Chakladar A, Bronson RT, Bernards A. Gastric hyperplasia in mice lacking the putative Cdc42 effector IQGAP1. Mol Cell Biol 2000; 20: 697-701.
134. Hirabayashi S, Mori H, Kansaku A, Kurihara H, Sakai T, Shimizu F, Kawachi H, Hata Y. MAGI-1 is a component of the glomerular slit diaphragm that is tightly associated with nephrin. Lab Invest 2005; 85: 1528-1543.
135. Inoue T, Yaoita E, Kurihara H, Shimizu F, Sakai T, Kobayashi T, Ohshiro K, Kawachi H, Okada H, Suzuki H, Kihara I, Yamamoto T. FAT is a component of glomerular slit diaphragms. Kidney Int 2001; 59: 1003-1012.
136. Moeller MJ, Soofi A, Braun GS, Li X, Watzl C, Kriz W, Holzman LB. Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J 2004;23:3769-3779.
137. Tanoue T, Takeichi M. New insights into Fat cadherins. J Cell Sci 2005; 118: 2347-2353.
138. Ciani L, Patel A, Allen ND, French-Constant C. Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype. Mol Cell Biol 2003; 23: 3575-3582.
139. Sun YP, Björklund M, Koivunen R. Screening of a phage library with human nephrin reveals MEGF1/Fat2 as a novel component of the podocyte slit diaphragm. J Am Soc Nephrol 2005; 16: 108A, abstract.
140. Quaggin SE. Transcriptional regulation of podocyte specification and differentiation. Microsc Res Tech 2002; 57: 208-211.
141. Wagner KD, Wagner N, Schedi A. The complex life of WT1. J Cell Sci 2003; 116: 1653-1658.
142. Yang Y, Jeanpierre C, Dressler GR, Lacoste M, Niaudet P, Gubler MC. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Am J Pathol 1999; 154: 181-192.
143. Ohtaka A, Ootaka T, Sato H, Soma J, Sato T, Saito T, Ito S. Significance of early phenotypic change of glomerular podocytes detected by Pax2 in primary focal segmental glomerulosclerosis. Am J Kidney Dis 2002; 39: 475-485.
144. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000; 58: 674-683.
145. Shankland SJ, Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 2000; 278: F515-F529.
146. Barbaux S, Niaudet P, Gubler MC, Grunfeld JP, Jaubert F, Kuttenn F, Fekete CN, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997; 17: 467-470.
147. Viney RL, Morrison AA, van den Heuvel LP, Ni L, Mathieson PW, Saleem MA, Ladomery MR. A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1. Proteomics 2007; 7: 804-815.
148. Dreyer SD, Zhou G, Baldini A, Winterpacht A, Zabel B, Cole W, Johnson RL, Lee B. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 1998; 19: 47-50.
149. Rohr C, Prestel J, Heidet L, Hosser H, Kriz W, Johnson RL, Antignac C, Witzgall R. The LIMhomeodomain transcription factor Lmx1b plays a crucial role in podocytes. J Clin Invest 2002; 109: 1073-1082.
150. Suleiman H, Heudobler D, Raschta AS, Zhao Y, Zhao Q, Hertting I, Vitzthum H, Moeller MJ, Holzman LB, Rachel R, Johnson R, Westphal H, Rascie A, Witzgall R. The podocyte-specific inactivation of Lmx1b, Ldb1 and E2a yields new insight into a transcriptional network in podocytes. Dev Biol 2007; 304: 701-712.
151. Quaggin SE, Schwartz L, Cui S, Igarashi P, Deimling J, Post M, Rossant J. The basic-helix-loophelix protein pod1 is critically important for kidney and lung organogenesis. Development 1999; 126: 5771-5783.
152. Sadl V, Jin F, Yu J, Cui S, Holmyard D, Quaggin S, Barsh G, Cordes S. The mouse Kreisler (Krml1/MafB) segmentation gene is required for differentiation of glomerular visceral epithelial cells. Dev Biol 2002; 249: 16-29.
153. Liu G, Clement LC, Kanwar YS, Avila-Casado C, Chugh SS. ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome. J Biol Chem 2006; 281: 39681-39692.
154. Di Duca M, Oleggini R, Sanna-Cherchi S, Pasquali L, Di Donato A, Parodi S, Bertelli R, Caridi G, Frasca G, Cerullo G, Amoroso A, Schena FP, Scolari F, Ghiggeri GM, European IgA Nephropathy Consortium. Cis and trans regulatory elements in NPHS2 promoter: implications in proteinuria and progression of renal disease. Kidney Int 2006; 70: 1332-1341.
155. Corre S, Galibert MD. Upstream stimulating factors: highly versatile stress-responsive transcription factors. Pigment Cell Res 2005; 18: 337-348.
156. Ross MD, Martinka S, Mukherjee A, Sedor JR, Vinson C, Bruggeman LA. Math6 expression during kidney development and altered expression in a mouse model of glomerulosclerosis. Dev Dyn 2006; 235: 3102-3109.
157. Takemoto M, He L, Norlin J, Patrakka J, Xiao Z, Petrova T, Bondjers C, Asp J, Wallgard E, Sun Y, Samuelsson T, Mostad P, Lundin S, Miura C, Sado Y, Alitalo K, Quaggin SE, Tryggvason K, Betsholtz C. Large-scale identification of genes implicated in kidney glomerulus development and function. EMBO J 2006; 25: 1160-1174.
158. Regele HM, Filipovic E, Langer B, Poczewski H, Kraxberger I, Bittner RE, Kerjaschki D. Glomerular expression of dystroglycans is reduced in minimal change nephrosis, but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000; 11: 403-412.
159. Raats CJ, van den Born J, Bakker MA, Oppers-Walgreen B, Pisa BJ, Dijkman HB, Assmann KJ, Berden JH. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 2000; 156: 1749-1765.
160. Tisi D, Talts JF, Timpl R, Honenester E. Structure of the C-terminal laminin G-like domain pair of the laminin α2 chain harbouring binding sites for α-dystroglycan and heparin. EMBO J 2000; 19: 1432-1440.
161. Williamson RA, Henry MD, Daniels KJ, Hrstka RF, Lee JC, Sunada Y, Ibraghimov-Beskrovnaya O, Campbell KP. Dystroglycan is essential for early embryonic development: disruption of Reicherts membrane in Dag1-null mice. Hum Mol Genet 1997; 6: 831-841.
162. Good KS, O'Brien K, Schulman G, Kerjaschki D, Fogo AB. Unexplained nephrotic-range proteinuria in a 38-year old man: a case of "no change disease." Am J Kidney Dis 2004; 43: 933-938.
163. Kretzler M, Teixeira VP, Unschuld PG, Cohen CD, Wanke R, Edenhofer I, Mundel P, Schlondorff D, Holthofer H. Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J 2001; 15: 1843-1845.
164. Adler S, Chen X. Anti-Fx1A antibody recognizes a β1-integrin on glomerular epithelial cells and inhibits adhesion and growth. Am J Physiol 1992; 262: F770-F776.
165. Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, Jaenisch R. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996; 122: 3537-3547.
166. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001; 155: 505-510.
167. Jung KY, Chen K, Kretzler M, Wu C. TGF-β1 regulates the PINCH-1-integrin-linked kinase-α-parvin complex in glomerular cells. J Am Soc Nephrol 2007; 18: 66-73.
168. Novak A, Hsu SC, Leung-Hagesteijn C, Radeva G, Papkoff J, Montesano R, Roskelley C, Grosschedl R, Dedhar S. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci USA 1998, 95: 4374-4379.
169. El-Aouni C, Herbach N, Blattner SM, Henger A, Rastaldi M, Jarad G, Miner JH, Moeller MJ, St-Arnaud R, Dedhar S, Holzman LB, Wanke R, Kretzler M. Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol 2006; 17: 1334-1344.
170. Dai C, Stolz DB, Bastacky SI, St.-Arnaud R, Wu C, Dedhar S, Liu Y. Essential role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 2006; 17: 2164-2175.
171. Whiteside CI, Cameron R, Munk S, Levy J. Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis. Am J Pathol 1993; 142: 1641-1653.
172. Bariety J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53: 918-925.
173. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285: F40-F48.
174. Kretzler M. Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech 2002; 57: 247-253.
175. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL. Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 1995; 270: 16995-16999.
176. Schrijvers BF, Flyvbjerg A, De Virese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
177. Datta K, Li J, Karumanchi SA, Wang E, Rondeau E, Mukhopadhyay D. Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes. Kidney Int 2004; 66: 1471-1478.
178. Freeburg PB, Robert B, St. John PL, Abrahamson DR. Podocyte expression by hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol 2003; 14: 927-938.
179. Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002; 13: 544-550.
180. Kang DH, Johnson RJ. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003; 12: 43-49.
181. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7: 661-666.
182. Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 2006; 17: 1886-1895.
183. Eremina V, Cui S, Gerber H, Ferrara N, Haigh J, Nagy A, Ema M, Rossant J, Jothy S, Miner JH, Quaggin SE. Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735.
184. Noris M, Perico N, Remuzzi G. Mechanisms of disease: preeclampsia. Nat Clin Pract Nephrol 2005; 1: 98-114.
185. Maynard S, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
186. Lindheimer MD. Unraveling the mysteries of preeclampsia. Am J Obstet Gynecol 2005; 193: 3-4.
187. Bdolah Y, Palomaki GE, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006; 194: 239-245.
188. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
189. Zhu X, Wu S, Dahut W, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
190. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007;71: 637-645.
191. Kobayashi N, Gao S, Chen J, Saito K, Miyawaki K, Li CY, Pan L, Saito S, Terashita T, Matsuda S. Process formation of the renal glomerular podocyte: is there common molecular machinery for processes of podocytes and neurons. Anat Sci Int 2004; 79: 1-10.
192. Rastaldi MP, Armelloni S, Berra S, Calvaresi N, Corbelli A, Giardino LA, Li M, Wang GO, Fornasieri A, Villa A, Heikkila E, Soliymani R, Boucherot A, Cohen CD, Kretzler M, Nitsche A, Ripamonti M, Malgaroli A, Pesaresi M, Forloni GL, Schlondorff D, Holthofer H, D'Amico G. Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J 2006; 20: 976-978.
193. Beltcheva O, Kontusaari S, Fetissov S, Putaala H, Kilpelainen P, Hokfelt T, Tryggvason K. Alternatively used promoters and distinct elements direct tissue-specific expression of nephrin. J Am Soc Nephrol 2003; 14: 352-358.
194. Kobayashi N, Reiser J, Kriz W, Kuriyama R, Mundel P. Non-uniform microtubular polarity, established by CHO1/MKLP1 motor protein, is necessary for process formation of podocytes. J Cell Biol 1998; 143: 1961-1970.
195. Simons M, Saffrich R, Reiser J, Mundel P. Directed membrane transport is involved in process formation in cultured podocytes. J Am Soc Nephrol 1999; 10: 1633-1639.
196. Rastaldi MP, Armelloni S, Berra S, Li M, Pesaresi M, Poczewski H, Langer B, Kerjaschki D, Henger A, Blattner SM, Kretzler M, Wanke R, D'Amico G. Glomerular podocytes possess the synaptic vesicle molecule Rab3A and its specific effector Rabphilin-3a. Am J Pathol 2003; 163: 889-899.
197. Cormont M, Meton I, Mari M, Monzo P, Keslair F, Gaskin C, McGraw TE, Le Marchand-Brustel Y. CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl. Traffic 2003; 4: 97-112.
198. Peitsch WK, Hofmann I, Endlich N, Pratzel S, Kuhn C, Spring H, Grone HJ, Kriz W, Franke WW. Cell biological and biochemical characterization of drebrin complexes in mesangial cells and podocytes of renal glomeruli. J Am Soc Nephrol 2003; 14: 1452-1463.
199. Gloy J, Reitinger S, Fischer KG, Schreiber R, Boucherot A, Kunzelmann K, Mundel P, Pavenstadt H. Amino acid transporter in podocytes. Am J Physiol Renal Physiol 2000; 278: F999-F1005.
200. Thomas PE, Wharram BL, Goyal M, Wiggins JE, Holzman LB, Wiggins RC. GLEPP1, a renal glomerular epithelial cell (podocyte) membrane protein-tyrosine phosphatase. J Biol Chem 1994; 269: 19953-19962.
201. Yang DH, Goyal M, Sharif K, Kershaw D, Thomas P, Dysko R, Wiggins R. Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man. Lab Invest 1996; 74: 571-584.
202. Wharram BL, Goyal M, Gillespie PJ, Wiggins JE, Kershaw DG, Holzman LB, Dysko RC, Saunders TL, Samuelson LC, Wiggins RC. Altered podocyte structure in GLEPP1 (Pt-pro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000; 106: 1281-1290.
203. Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, Reiser J, Mundel P. Synaptopodin regulates the actin-bundling activity of α-actinin in an isoform-specific manner. J Clin Invest 2005; 115: 1188-1198.
204. Deller T, Korte M, Chabanis S, Drakew A, Schwegler H, Stefani GG, Zuniga A, Schwarz K, Bonhoeffer T, Zeller R, Frotscher M, Mundel P. Synaptopodin-deficient mice lack a spine apparatus and show deficits in synaptic plasticity. Proc Natl Acad Sci USA 2003; 100: 10494-10499.
205. Kemeny E, Durmuller U, Nickeleit V, Gudat F, Mihatsch MJ. Distribution of podocyte protein (44 KD) in different types of glomerular diseases. Virchows Arch 1997; 431: 425-430.
206. Paul MD, Fernandez D, Pryse-Phillips W, Gault MH. Charcot-Marie-Tooth disease and nephropathy in a mother and daughter with a review of the literature. Nephron 1990; 54: 80-85.
207. Plaisier E, Mougenot B, Verpont MC, Jouanneau C, Archelos JJ, Martini R, Kerjaschki D, Ronco P. Glomerular permeability is altered by loss of P0, a myelin protein expressed in glomerular epithelial cells. J Am Soc Nephrol 2005; 16: 3350-3364.
208. Gross O, Beirowski B, Harvey SJ, McFadden C, Chen D, Tam S, Thorner PS, Smyth N, Addicks K, Bloch W, Ninomiya Y, Sado Y, Weber M, Vogel WF. DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. Kidney Int 2004; 66: 102-111.
209. Miyauchi N, Saito A, Karasawa T, Harita Y, Suzuki K, Koike H, Han GD, Shimizu F, Kawachi H. Synaptic vesicle protein 2B is expressed in podocyte, and its expression is altered in proteinuric glomeruli. J Am Soc Nephrol 2006; 17: 2748-2759.
210. Guan F, Villegas G, Teichman J, Mundel P, Tufro A. Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival. Kidney Int 2006; 69: 1564-1569.
211. Tamagnone L, Comoglio PM. To move or not to move? Semaphorin signalling in cell migration. EMBO Rep 2004; 5: 356-361.
212. Kriz W. TRPC6 - a new podocyte gene involved in focal segmental glomerulosclerosis. Trends Mol Med 2005; 11: 527-530.
213. Koziell A, Grech V, Hussain S, Lee G, Lenkkeri U, Tryggvason K, Scambler P. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional interrelationship in glomerular filtration. Hum Mol Genet 2002; 11: 379-388.
214. Caridi G, Bertelli R, Carrea A, Di Duca M, Catarsi P, Artero M, Carraro M, Zennaro C, Candiano G, Musante L, Seri M, Ginevri F, Perfumo F, Ghiggeri GM. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12: 2742-2746.
215. Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13: 388-393.
216. Tsukaguchi H, Yager H, Dawborn J, Jost L, Cohlmia J, Abreu PF, Pereira AB, Pollak MR. A locus for adolescent and adult onset familial focal segmental glomerulosclerosis on chromosome 1q25-31. J Am Soc Nephrol 2000; 11: 1674-1680.
217. Weber S, Gribouval O, Esquivel EL, Moriniere V, Tete MJ, Ledendre C, Niaudet P, Antignac C. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66: 571-579.
218. Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res 2005; 57: 54R-61R.
219. He N, Zahirieh A, Mei Y, Lee B, Senthilnathan S, Wong B, Mucha B, Hildebrandt F, Cole DE, Cattran D, Pei Y. Recessive NPHS2 (podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 31-37.
220. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722-732.
221. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5: 1179-1185.
222. Becker-Cohen R, Bruschi M, Rinat C, Feinstein S, Zennaro C, Ghiggeri CM, Frishberg Y. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007; 7: 256-260.
223. Frishberg Y, Feinstein S, Rinat C, Becker-Cohen R, Lerer I, Raas-Rothschild A, Ferber B, Nir A. The heart of children with steroid-resistant nephrotic syndrome: is it all podocin? J Am Soc Nephrol 2006; 17: 227-231.
224. Blum S, Nakhoul F, Khankin E, Abassi Z. Renal slit diaphragm - the open zipper and the failing heart. Isr Med Assoc J 2007; 9: 107-111.
225. Pereira AC, Pereira AB, Mota GF, Cunha RS, Herkenhoff FL, Pollak MR, Mill JG, Krieger JE. NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int 2004; 65: 1026-1030.
226. Franceschini N, North KE, Kopp JB, McKenzie L, Winkler C. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review. Genet Med 2006; 8: 63-75.
227. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256.
228. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H, Kalluri R, Gerszten RE, Pollak MR. Mice deficient in α-actinin-4 have severe glomerular disease. J Clin Invest 2003; 111: 1683-1690.
229. Michaud JL, Chaisson KM, Parks RJ, Kennedy CR. FSGS-associated α-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 2006; 70: 1054-1061.
230. Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR. Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PloS Biol 2004; 2: e167.
231. Winn M, Conlon P, Lynn K, Howell DN, Slotterbeck BD, Smith AH, Graham FL, Bembe M, Quarles LD, Pericak-Vance MA, Vance JM. Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999; 58: 113-120.
232. Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007; 18: 29-36.
233. Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, Unanue ER, Shaw AS. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003; 300: 1298-1300.
234. Huber TB, Kwoh C, Wu H, Asanuma K, Godel M, Hartleben B, Blumer KJ, Miner JH, Mundel P, Shaw AS. Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest 2006; 116: 1337-1345.
235. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyel M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkalolu A, Cleper R, Base-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O'Toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzmann LB, Nurnberg P, Hildebrandt F. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Gen 2006; 38: 1397-1405.
236. Bunney TD, Katan M. Phospholipase C epsilon: linking second messengers and small GTPases. Trends Cell Biol 2006; 16: 640-648.
237. Wang H, Oestreich EA, Maekawa N, Bullard TA, Vikstrom KL, Dirksen RT, Kelley GG, Blaxall BC, Smrcka AV. Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res 2005; 97: 1305-1313.
238. Bongers EM, Gubler MC, Knoers NV. Nail-patella syndrome: overview on clinical and molecular findings. Pediatr Nephrol 2002; 17: 703-712.
239. Wuhl E, Kogan J, Zurowska A, Matejas V, Vandevoorde RG, Aigner T, Wendler O, Lesniwska I, Bouvier R, Reis A, Weis J, Cochat P, Zenkter M. Neurodevelopmental deficits in Pierson (microcoriacongenital nephrosis) syndrome. Am J Med Genet 2007; 15: 311-319.
240. Arfeen S, Rosborough D, Luger AM, Nolph KD. Familial unilateral renal agenesis and focal and segmental glomerulosclerosis. Am J Kidney Dis 1993; 21: 663-668.
241. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L. Germline mutations in the Wilms tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991; 67: 437-447.
242. Orloff MS, Iyengar SK, Winkler CA, Dart RA, Ahuja TS, Mokrzycki M, Briggs WA, Korbet SM, Kimmel PL, Simon EE, Trachtman H, Vlahov D, Michel DM, Berns JS, Smith MC, Schelling JR, Sedor JR, Goddard KA, Kopp JB. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics 2005; 21: 212-221.
243. Kambham N, Tanji N, Seigle RL, Markowitz GS, Pulkkinen L, Uitto J, D'Agati VD. Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. Am J Kidney Dis 2000; 36: 190-196.
244. Comper WD, Glasgow EF. Charge selectivity in kidney ultrafiltration. Kidney Int 1995; 47: 1242-1251
245. Goode NP, Shires M, Davison AM. The glomerular basement membrane charge-selectivity barrier: an oversimplified concept? Nephrol Dial Transplant 1996; 11: 1714-1716.
246. Bridges CR, Myers BD, Brenner BM, Deen WM. Glomerular charge alterations in human minimal change nephropathy. Kidney Int 1982; 22: 677-684.
247. Shemesh O, Ross JC, Deen WM, Grant GW, Myers BD. Nature of the glomerular capillary injury in human membranous glomerulopathy. J Clin Invest 1986; 77: 868-877.
248. Myers BD, Guasch A. Mechanisms of proteinuria in nephrotic humans. Pediatr Nephrol 1994; 8: 107-112.
249. Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, Kestila M, Koskimies O, Jalanko H. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 2004; 15: 2611-2618.
250. Shah S, Baliga R, Rajapukar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18: 16-28.
251. Hagiwara M, Yamagata K, Capaldi RA, Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006; 69: 1146-1152.
252. Ricardo SD, Bertram JF, Ryan GB. Reactive oxygen species in puromycin aminonucleoside nephrosis: in vitro studies. Kidney Int 1994; 45: 1057-1069.
253. Ricardo SD, Bertram JF, Ryan GB. Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 1994; 4: 1974-1986.
254. Zima T, Tesar V, Crkovska J, Stejskalova A, Platenik J, Teminova J, Nemecek K, Janebova M, Stipek S. ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats. Nephrol Dial Transplant 1998; 13: 1975-1979.
255. Koshikawa M, Mukoyama M, Mori K, Saganami T, Sawai K, Yoshioka T, Nagae T, Yokoi H, Kawachi H, Shimizu F, Sugiwara A, Nakao K. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
256. Luimula P, Ahola H, Wang SX, Solin ML, Aaltonen P, Tikkanen I, Kerjaschki D, Holthofer H. Nephrin in experimental glomerular disease. Kidney Int 2000; 58: 1461-1468.
257. Shaloub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 2: 556.
258. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878-883.
259. Garin EH. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2000; 14: 872-878.
260. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14.
261. Sharma M, Sharma R, McCarthy ET, Savin VJ. "The FSGS factor": enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10: 552-561.
262. Trachtman H, Futterweit S, Singhal PC, Franki N, Sharma M, Sharma R, Savin V. Circulating factor in patients with recurrent focal segmental glomerulosclerosis postrenal transplantation inhibits expression of inducible nitric oxide synthase and nitric oxide production by cultured rat mesangial cells. J Invest Med 1999; 47: 114-120.
263. Koyama A, Fukisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40: 453-460.
264. Sahali D, Pawlak A, Valanciuté A, Grimbert P, Lang P, Remy P, Bensman A, Guellaen G. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 2002; 13: 1238-1247.
265. Cunard R, Kelly CJ. T cells and minimal change disease. J Am Soc Nephrol 2002; 13: 1409-1411.
266. Carraro M, Caridi G, Bruschi M, Artero M, Bertelli R, Zennaro C, Musante L, Candiano G, Perfumo F, Ghiggeri GM. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13: 1946-1952.
267. Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003; 14: 448-453.
268. Sharma R, Sharma M, McCarthy ET, Ge XL, Savin VJ. Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 2000; 58: 1973-1979.
269. Candiano G, Musante L, Carraro M, Faccini L, Campanacci L, Zennaro C, Artero M, Ginevri F, Perfumo F, Gusmano R, Ghiggeri GM. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12: 143-150.
270. Ghiggeri GM, Artero M, Carraro M, Perfumo F. Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor. Nephrol Dial Transplant 2001; 16: 882-885.
271. Musante L, Candiano G, Bruschi M, Zennaro C, Carrato M, Artero M, Giuffrida MG, Conti A, Santucci A, Ghiggeri GM. Characterization of plasma factors that alter the permeability to albumin within isolated glomeruli. Proteomics, 2002; 2: 197-205.
272. Ghiggeri GM, Bruschi M, Candiano G, Rastaldi MP, Scolari F, Passerini P, Musante L, Pertica N, Caridi G, Ferrario F, Perfumo F, Ponticelli C. Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 2002; 62: 2184-2194.
273. Carraro M, Zennaro C, Candiano G, Musante L, Bruschi M, Ghiggeri GM, Artero M, Faccini L. Nephrotic urine prevents increased rat glomerular albumin permeability induced by serum from the same patient with idiopathic nephrotic syndrome. Nephrol Dial Transplant 2003; 18: 689-693.
274. Sharma M, Sharma R, McCarthy ET, Savin VJ. The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 2004; 229: 85-98.
275. Doublier S, Musante L, Lupia E, Candiano G, Spatola T, Caridi G, Zennaro C, Carraro M, Ghiggeri GM, Camussi G. Direct effect of plasma permeability factors from patients with idiopathic FSGS on nephrin and podocin expression in human podocytes. Int J Mol Med 2005; 16: 49-58.
276. Marszal J, Saleem MA. The bioactivity of plasma factors in focal segmental glomerulosclerosis. Nephron Exp Nephrol 2006; 104: e1-e5.
277. Furness PN, Hall LL, Shaw JA, Pringle JH. Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. Nephrol Dial Transplant 1999; 14: 1234-1237.
278. Patrakka J, Ruotsalainen V, Ketola I, Holmberg C, Heikinheimo M, Tryggvason K, Jalanko H. Expression of nephrin in pediatric kidney diseases. J Am Soc Nephrol 2001; 12: 289-296.
279. Koop K, Eikmans M, Baelde HJ, Kawachi H, de Heer E, Leendert CP, Bruijn JA. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-2071.
280. Mao J, Zhang Y, Du L, Dai Y, Yang C, Liang L. Expression profile of nephrin, podocin, and CD2AP in Chinese children with MCNS and IgA nephropathy. Pediatr Nephrol 2006; 21: 1666-1675.
281. Schmid H, Henger A, Cohen CD, Frach K, Grone HJ, Schlondorff D, Kretzler M. Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol 2003; 14: 2958-2966.
282. Szeto CC, Lai KB, Chow KM, Szeto CY, Yip TW, Woo KS, Li PK, Lai FM. Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta 2005; 361: 182-190.
283. Sharif K, Goyal M, Kershaw D, Kunkel R, Wiggins R. Podocyte phenotypes as defined by expression and distribution of GLEPP-1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome. Exp Nephrol 1998; 6: 234-244.
284. Devarajan P, Spitzer A. Towards biological characterization of focal segmental glomerulosclerosis. Am J Kidney Dis 2002; 39: 625-636.
285. Tanawattanacharoen S, Falk R, Jennette C, Kopp JB. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 2000; 35: 1166-1174.
286. Ingulli E, Tejani A. Incidence, treatment and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children: a single-center experience. Transplantation 1991; 51: 401-405.
287. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23: 574-581.
288. Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, Hirschberg R, Adler SG. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998; 32: 230-237.
289. Srivastava T, Garola RE, Whiting JM, Alon US. Synaptopodin expression in idiopathic nephrotic syndrome of childhood. Kidney Int 2001; 59: 118-125.
290. Mrowka C, Schedl A. Wilms tumor suppressor gene WT1: from structure to renal pathophysiologic features. J Am Soc Nephrol 2000; 11 (Suppl 16): S106-S115.
291. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z. Apoptosis in glomerular sclerosis. Kidney Int 1996; 49: 103-111.
292. Ortiz A. Apoptotic regulatory proteins in renal injury. Kidney Int 2000; 58: 467-485.
293. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999; 18: 3990-4003.
294. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816.
295. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Hozman LB, Wiggins RC. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
296. Schwab K, Witte DP, Aronow BJ, Devarajan P, Potter SC, Patterson LT. Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol 2004; 24: 438-447.
297. Albaqumi M, Soos TJ, Barisoni L, Nelson PJ. Collapsing glomerulopathy. J Am Soc Nephrol 2006; 17: 2854-2863.
298. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000; 58: 137-143.
299. Shah SN, He CJ, Klotman P. Update on HIV-associated nephropathy. Curr Opin Nephrol Hypertens 2006; 15: 450-455.
300. Husain M, D'Agati V, He JC, Klotman ME, Klotman PE. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS 2005; 19: 1975-1980.
301. Doublier S, Zennaro C, Spatola T, Lupia E, Bottelli A, Deregibus MC, Carraro M, Conaldi, PG, Camussi G. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007; 21: 423-432.
302. Nelson PJ, Shankland SJ. Therapeutics in renal disease: The road ahead for antiproliferative targets. Nephron Exp Nephrol 2006; 103: e6-e15.
303. Gherardi D, D'Agati V, Chu TH, Barnett A, Gianella-Borradori A, Gelman IH, Nelson PJ. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004; 15: 1212-1222.
304. Soos TJ, Meijer L, Nelson PJ. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases. Drug News Perspect 2006; 19: 314-317.
305. Vaughan MR, Pippin J, Griffin SV, Kroft R, Fleet M, Haseley L, Shankland SJ. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 2005; 68: 133-144.
306. Hermann M, Shaw S, Kiss E, Camici G, Buhler N, Chenevard R, Luscher TF, Grone HJ, Ruschitzka F. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005; 45: 193-197.
307. Heckmann A, Waltzinger C, Jolicoeur P, Dreano M, Kosco-Vilbois MH, Sagot Y. IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS. Am J Pathol 2004; 164: 1253-1262.
308. Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006; 48: 772-779.
309. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, De Cosmo S, Viberti G. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51: 3083-3089.
310. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
311. Kriz W. Podocyte is the major culprit accounting for the progression of chronic disease. Microvasc Res Tech 2002; 57: 189-195.
312. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.
313. Praga M. Obesity - a neglected culprit in renal disease. Nephrol Dial Transplant 2002; 17: 1157-1159.
314. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
315. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 1982; 79: 5557-5561.
316. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschenes G, Ronco PM. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346: 2053-2060.
317. Ronco P, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol 2006; 17: 1772-1774.
318. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1195-1204.
319. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 1980; 66: 1339-1350.
320. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 1989; 135: 185-194.
321. Matsuo S, Morita Y, Yuzawa Y, Maruyama S. Urinary membrane attack complex (MAC) is a potent predictor of poor renal outcome in proteinuric glomerular diseases. J Am Soc Nephrol 2004; 15: 328A, abstract.
322. Greiber S, Munzel T, Kastner S, Muller B, Schollmeyer P, Pavenstadt H. NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 1998; 53: 654-663.
323. Takano T, Cybulsky AV, Cupples WA, Ajikobi DO, Papillon J, Aoudjit L. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J Pharmacol Exp Ther 2003; 305: 240-249.
324. Minto AW, Kalluri R, Togawa M, Bergijk EC, Killen PD, Salant DJ. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy. Proc Assoc Am Physicians 1998; 110: 207-217.
325. Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG. Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 1996; 50: 116-124.
326. Topham PS, Haydar SA, Kuphal R, Lightfoot JD, Salant DJ. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 1999; 55: 1763-1775.
327. Moll S, Lange S, Mihatsch MJ, Dragic Z, Schifferli JA, Inal JM. CRIT is expressed on podocytes in normal human kidney and upregulated in membranous nephropathy. Kidney Int 2006; 69: 1961-1968.
328. Yuan H, Takeuchi E, Taylor GA, McLaughlin M, Brown D, Salant DJ. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002; 13: 946-956.
329. Nakatsue T, Koike H, Han GD, Suzuki K, Miyauchi N, Yuan H, Salant DJ, Gejyo F, Shimizu F, Kawachi H. Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney Int 2005; 67: 2239-2353.
330. Kim BK, Hong HK, Kim JH, Lee HS. Differential expression of nephrin in acquired human proteinuric diseases. Am J Kidney Dis 2002; 40: 964-973.
331. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001; 12: 941-948.
332. Nitschke R, Henger A, Ricken S, Gloy J, Muller V, Greger R, Pavenstadt H. Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. Kidney Int 2000; 57: 41-49.
333. Remuzzi A, Monaci N, Bonassi ME, Corna D, Zoja C, Mohammed EI, Remuzzi G. Angiotensinconverting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive Heymann nephritis. Lab Invest 1999; 79: 1501-1510.
334. Ding G, Reddy K, Kapasi AA, Franki N, Gibbons N, Kasinath BS, Singhal PC. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283: F173-F180.
335. Nagata M, Yamaguchi Y, Komatsu Y, Ito K. Mitosis and the presence of binucleate cells among glomerular podocytes in diseased human kidneys. Nephron 1995; 70: 68-71.
336. Shankland SJ, Pippin J, Couser WG. Complement (C5b-9) induces glomerular epithelial cell DNA synthesis but not proliferation in vitro. Kidney Int 1999; 56: 538-548.
337. Hara M, Yanagihara T, Kihara I. Apical cell membranes are shed into urine from injured podocytes in IgA nephropathy: proposal of hypothesis about podocyte injury. Nephrology 2004; 9: A51, abstract.
338. Kanno K, Kawachi H, Uchida Y, Hara M, Shimizu F, Uchiyama M. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract 2003; 95: c91-c99.
339. Saleem M. Urine - a mirror of the (glomerular) soul? Nephron Clin Pract 2003; 95: c75-c76.
340. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000; 20: 373-379.
341. Gagliardini E, Benigni A, Tomasoni S, Abbate M, Kalluri R, Remuzzi G. Targeted downregulation of extracellular nephrin in human IgA nephropathy. Am J Nephrol 2003; 23: 277-286.
342. Qiu LQ, Sinniah R, Hsu SI. Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy. J Am Soc Nephrol 2004; 15: 79-90.
343. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
344. Han TS, Schwartz MM, Lewis EJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus 2006; 15: 71-75.
345. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF-κB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Arch 2006; 448: 172-183.
346. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 2006; 54: 1626-1634.
347. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 162-182.
348. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-882.
349. Han SY, Kang YS, Jee YH, Han KH, Cha DR, Kang SW, Han DS. High glucose and angiotensin II increase beta 1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res 2006; 323: 321-332.
350. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim JS, Kim HJ, Han SH, Lee JE, Han DS, Kang SW. Activation of the renin-angiotensin system within podocytes in diabetics. Kidney Int 2007; 71: 1019-1027.
351. Huang XR, Chen WY, Truong LD, Lan HY, Wang SX. Chymase is upregulated in diabetic nephropathy: implications of an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738-1747.
352. Ziadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004; 15 (Suppl 1): S55-S57.
353. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003; 305: 1002-1007.
354. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-1344.
355. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035.
356. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15: 1475-1487.
357. Gross ML, El-Shakmak A, Szabo A, Koch A, Kuhlmann A, Munter K, Ritz E, Amann K. ACEinhibitors, but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003; 46: 856-868.
358. Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham R, Panagiotopoulos S, Jerums G, Holthofer H, Gilbert RE. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002; 17: 1327-1332.
359. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003; 21: 209-216.
360. Petermann AT, Pippin J, Krofft R, Blonski M, Griffin S, Durvasula R, Shankland SJ. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004; 98: e114-e123.
361. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 2000; 67: 2345-2353.
362. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Tsilibary EC. Glucosei-nduced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003; 284: F671-F679.
363. Kagami S, Border WA, Ruoslahti E, Noble NA. Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest 1993; 69: 68-76.
364. Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, Hidaka S, Ebihara K, Tanaka T, Sugawara A, Kawachi H, Vinson C, Ogawa Y, Nakao K. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J 2005; 19: 127-129.
365. Khoshnoodi J, Sigmundsson K, Ofverstedt LG, Skoglund U, Obrink B, Wartiovaara J, Tryggvason K. Nephrin promotes cell-cell adhesion through homophilic interactions. Am J Pathol 2003; 163: 2337-2346.
366. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
367. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
368. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of α3(IV) collagen production by transforming growth factor-β1 in mouse podocytes. Diabetes 2004; 53: 2939-2949.
369. Aaltonen P, Luimula P, Astrom E, Palmen T, Gronholm T, Palojoki E, Jaakkola I, Ahola H, Tikkanen I, Holthofer H. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001; 81: 1185-1190.
370. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. Nephrin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030.
371. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, Remuzzi G. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65: 2193-2200.
372. Langham RG, Kelly DJ, Cox AJ, Gow AJ, Holthofer H, Gilbert RE. Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant 2004; 19: 262-263.
373. Palmen T, Ahola H, Palgi J, Aaltonen P, Luimula P, Wang S, Jaakkola I, Knip M, Otonkoski T, Holthofer H. Nephrin is expressed in the pancreatic beta cells. Diabetologia 2001; 44: 1274-1280.
374. Aaltonen P, Rinta-Valkama J, Patari A, Tossavainen P, Palmen T, Kulmala P, Knip M, Holthofer H. Circulating antibodies to nephrin in patients with type 1 diabetes. Nephrol Dial Transplant 2007; 22: 146-153.
375. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS, AIPRD Study Group (Angiotensin-Converting Enzyme Inhibition and Progression of Renal Disease). Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140.
376. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a metaanalysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974.
377. Don BR, Kaysen GA, Huchison FN, Schambelan M. The effect of angiotensin-converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria. Am J Kidney Dis 1991; 17: 10-17.
378. Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstadt H, Fischer KG. Functional expression of the renin angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 27: F710-F719.
379. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14: 2833-2842.
380. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364.
381. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental chronic renal failure. Nephrol Dial Transplant 1996; 11: 1003-1011.
382. Yamauchi K, Takano Y, Kasai A, Hayakawa K, Hiramatsu N, Enomoto N, Yao J, Kitamura M. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 2006; 70: 892-900.
383. Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, Alique M, Chen S, Ziyadeh FN, Iglesiasde la Cruz MC, Rodriguez J, Nieto E, Orellana JM, Reyes P, Ambas I, Xu Q, Kitamura M, Lucio Cazana FJ. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 2003; 139: 823-831.
384. He JC, Lu TC, Fleet M, Sunamoto M, Husain M, Fang W, Neves S, Chen Y, Shankland S, Iyengar R, Klotman PE. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007; 18: 93-102.
385. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K. 1,25-dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
386. Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005; 68: 2473-2483.
387. Ransom RF, Vega-Warner V, Smoyer WE, Klein J. Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes. Kidney Int 2005; 67: 1275-1285.
388. Miyata T, Inagi R, Sugiyama S, Usuda N. Serpinopathy and endoplasmic reticulum stress. Med Mol Morphol 2005; 38: 73-78.
389. Inagi R, Nangaku M, Onogi H, Ueyama H, Kitao Y, Nakazato K, Ogawa S, Kurokawa K, Couser WG, Miyata T. Involvement of endoplasmic reticulum (ER) stress in podocyte injury by excessive protein accumulation. Kidney Int 2005; 68: 2639-2650.
390. Fujii Y, Khoshnoodi J, Takenaka H, Hosoyamada M, Nakajo A, Bessho F, Kudo A, Takahashi S, Arimura Y, Yamada A, Nagasawa T, Ruotsalainen V, Tryggvason K, Lee AS, Yan K. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006; 69: 1350-1359.
391. Kim BS, Park HC, Kang SW, Choi KH, Ha SK, Han DS, Lee HY. Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis in rats. Yonsei Med J 2005; 46: 141-148.
392. Zima T, Tesar V, Stipek S, Crkovska J, Poledne R, Teminova J, Platenik J, Rychlik I, Merta M, Nemecek K. The influence of cyclosporin on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron 1997; 75: 464-468.
393. Hocker B, Knuppel T, Waldherr R, Schaefer F, Weber S, Tonshoff B. Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol 2006; 21: 1476-1479.
394. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849-2861.
395. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007; 49: 310-317.
396. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006; 70: 177-186.
397. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 2005; 16: 1936-1947.
398. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002; 61: 1635-1645.
399. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina H. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67: 427-431.
400. Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, Koide H. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentration in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001; 18: 308-313.
401. Agarwal R, Saha C, Battiwal M, Vasavad N, Curley T, Chase SD, Sachs N, Semret MH. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005; 68: 285-292.
402. Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006; 17: 1624-1632.
403. Suzuki A, Ito T, Imai E, Yamato M, Iwatani H, Kawachi H, Hori M. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003; 14: 981-991.
404. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870.
405. Milovanceva-Popovska M, Kunter U, Ostendorf T, Petermann A, Rong S, Eitner F, Kerjaschki D, Barnett A, Floege J. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int 2005; 67: 1362-1370.
406. Durvasula RB, Shankland SJ. Podocyte injury and targeting therapy: an update. Curr Opin Nephrol Hypertens 2006; 15: 1-7.